Promethazine hydrochloride and dextromethorphan hydrobromide, Nuedexta(dextromethorphan)
Auvelity, Bromanate, Bromfed-dm, Dimetane-dx, Mucinex, Nuedexta, Pherazine (dextromethorphan) is a small molecule pharmaceutical. Dextromethorphan was first approved as Promethazine hydrochloride and dextromethorphan hydrobromide on 1984-04-02. It is used to treat cough in the USA. It has been approved in Europe to treat neurobehavioral manifestations. It is known to target sigma non-opioid intracellular receptor 1 and glutamate receptor ionotropic, NMDA 2C.
Download report
Favorite
SARS-CoV-2 Interaction
Top OTC Drugs
Commercial
Trade Name
FDA
EMA
Combinations
Auvelity, Mucinex, Nuedexta (generic drugs available since 1985-01-04, discontinued: Bromanate, Bromfed-dm, Dimetane-dx, Pherazine)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Brompheniramine maleate
+
Dextromethorphan hydrobromide
+
Pseudoephedrine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
DIMETANE-DX | A.H. Robins Company | N-019279 DISCN | 1984-08-24 | 1 products, RLD |
Hide discontinued
Bupropion hydrochloride
+
Dextromethorphan hydrobromide
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
AUVELITY | Axsome Malta | N-215430 RX | 2022-08-18 | 1 products, RLD, RS |
Dextromethorphan hydrobromide
+
Guaifenesin
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
MUCINEX DM | RB Health | N-021620 OTC | 2004-04-29 | 2 products, RLD |
Dextromethorphan hydrobromide
+
Promethazine hydrochloride
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE | ANI PHARMS | N-011265 DISCN | 1984-04-02 | 1 products, RLD |
Hide discontinued
Dextromethorphan hydrobromide
+
Quinidine sulfate
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
NUEDEXTA | Avanir Pharmaceuticals | N-021879 RX | 2010-10-29 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
auvelity | New Drug Application | 2022-09-02 |
mucinex fast-max day cold and flu and night cold and flu | OTC monograph final | 2023-06-15 |
nuedexta | New Drug Application | 2022-11-30 |
severe cold and flu relief | OTC monograph final | 2023-06-19 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
cough | HP_0012735 | D003371 | R05 |
Agency Specific
FDA
EMA
Expiration | Code | ||
---|---|---|---|
BUPROPION HYDROCHLORIDE / DEXTROMETHORPHAN HYDROBROMIDE, AUVELITY, AXSOME | |||
2025-08-18 | NP |
Patent Expiration
Patent | Expires | Flag | FDA Information |
---|---|---|---|
Bupropion Hydrochloride / Dextromethorphan Hydrobromide, Auvelity, Axsome | |||
10780064 | 2040-01-07 | U-3419 | |
10925842 | 2040-01-07 | U-3419 | |
10940124 | 2040-01-07 | U-3419 | |
10966942 | 2040-01-07 | U-3419 | |
10780066 | 2034-11-09 | U-3419 | |
9168234 | 2034-11-05 | U-3419 | |
9198905 | 2034-11-05 | U-3419 | |
9205083 | 2034-11-05 | U-3419 | |
9238032 | 2034-11-05 | U-3419 | |
9278095 | 2034-11-05 | U-3419 | |
9314462 | 2034-11-05 | U-3419 | |
9370513 | 2034-11-05 | U-3419 | |
9375429 | 2034-11-05 | U-3419 | |
9408815 | 2034-11-05 | U-3419 | |
9421176 | 2034-11-05 | U-3419 | |
9457023 | 2034-11-05 | U-3419 | |
9457025 | 2034-11-05 | U-3419 | |
9474731 | 2034-11-05 | U-3419 | |
9486450 | 2034-11-05 | U-3419 | |
9700528 | 2034-11-05 | U-3419 | |
9700553 | 2034-11-05 | U-3419 | |
9707191 | 2034-11-05 | U-3419 | |
9763932 | 2034-11-05 | U-3419 | |
9861595 | 2034-11-05 | U-3419 | |
9867819 | 2034-11-05 | U-3419 | |
9968568 | 2034-11-05 | U-3419 | |
10058518 | 2034-11-05 | U-3419 | |
10064857 | 2034-11-05 | U-3419 | |
10080727 | 2034-11-05 | U-3419 | |
10092560 | 2034-11-05 | U-3419 | |
10092561 | 2034-11-05 | U-3419 | |
10105327 | 2034-11-05 | U-3419 | |
10105361 | 2034-11-05 | U-3419 | |
10251879 | 2034-11-05 | U-3419 | |
10463634 | 2034-11-05 | U-3419 | |
10512643 | 2034-11-05 | U-3419 | |
10548857 | 2034-11-05 | U-3419 | |
10596167 | 2034-11-05 | U-3419 | |
10772850 | 2034-11-05 | U-3419 | |
10786469 | 2034-11-05 | U-3419 | |
10786496 | 2034-11-05 | U-3419 | |
10799497 | 2034-11-05 | U-3419 | |
10806710 | 2034-11-05 | U-3419 | |
10864209 | 2034-11-05 | U-3419 | |
10874663 | 2034-11-05 | U-3419 | |
10874664 | 2034-11-05 | U-3419 | |
10874665 | 2034-11-05 | U-3419 | |
10881624 | 2034-11-05 | U-3419 | |
10881657 | 2034-11-05 | U-3419 | |
10894046 | 2034-11-05 | U-3419 | |
10894047 | 2034-11-05 | U-3419 | |
10898453 | 2034-11-05 | U-3419 | |
10933034 | 2034-11-05 | U-3419 | |
10945973 | 2034-11-05 | U-3419 | |
10966941 | 2034-11-05 | U-3419 | |
10966974 | 2034-11-05 | U-3419 | |
11020389 | 2034-11-05 | U-3419 | |
11058648 | 2034-11-05 | U-3419 | |
11090300 | 2034-11-05 | U-3419 | |
11096937 | 2034-11-05 | U-3419 | |
11123343 | 2034-11-05 | U-3419 | |
11129826 | 2034-11-05 | U-3419 | |
11141388 | 2034-11-05 | U-3419 | |
11141416 | 2034-11-05 | U-3419 | |
11147808 | 2034-11-05 | U-3419 | |
11185515 | 2034-11-05 | U-3419 | |
11191739 | 2034-11-05 | DP | U-3419 |
11197839 | 2034-11-05 | DP | U-3419 |
11207281 | 2034-11-05 | U-3419 | |
11213521 | 2034-11-05 | U-3419 | |
11229640 | 2034-11-05 | U-3419 | |
11234946 | 2034-11-05 | U-3419 | |
11253491 | 2034-11-05 | U-3419 | |
11253492 | 2034-11-05 | U-3419 | |
11273133 | 2034-11-05 | U-3419 | |
11273134 | 2034-11-05 | U-3419 | |
11285118 | 2034-11-05 | U-3419 | |
11285146 | 2034-11-05 | U-3419 | |
11291638 | 2034-11-05 | U-3419 | |
11291665 | 2034-11-05 | U-3419 | |
11298351 | 2034-11-05 | U-3419 | |
11298352 | 2034-11-05 | U-3419 | |
11311534 | 2034-11-05 | U-3419 | |
11344544 | 2034-11-05 | U-3419 | |
11357744 | 2034-11-05 | U-3419 | |
11364233 | 2034-11-05 | U-3419 | |
11382874 | 2034-11-05 | U-3419 | |
11419867 | 2034-11-05 | U-3419 | |
11426370 | 2034-11-05 | U-3419 | |
11426401 | 2034-11-05 | U-3419 | |
11433067 | 2034-11-05 | DP | U-3419 |
11439636 | 2034-11-05 | U-3419 | |
11478468 | 2034-11-05 | U-3419 | |
11497721 | 2034-11-05 | U-3419 | |
11510918 | 2034-11-05 | U-3419 | |
11517542 | 2034-11-05 | U-3419 | |
11517543 | 2034-11-05 | U-3419 | |
11524007 | 2034-11-05 | U-3419 | |
11524008 | 2034-11-05 | U-3419 | |
11534414 | 2034-11-05 | DP | U-3419 |
11541021 | 2034-11-05 | U-3419 | |
11541048 | 2034-11-05 | U-3419 | |
11596627 | 2034-11-05 | U-3419 | |
11617728 | 2034-11-05 | U-3419 | |
11617747 | 2034-11-05 | U-3563 | |
8569328 | 2033-10-29 | DP | U-3419 |
Dextromethorphan Hydrobromide / Quinidine Sulfate, Nuedexta, Avanir Pharms | |||
7659282 | 2026-08-13 | U-1093 | |
8227484 | 2023-07-17 | U-1093 |
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07X: Other nervous system drugs in atc
— N07XX: Other nervous system drugs in atc
— N07XX59: Dextromethorphan, combinations
R: Respiratory system drugs
— R05: Cough and cold preparations
— R05D: Cough suppressants, excl. combinations with expectorants
— R05DA: Opium alkaloids and derivatives, cough suppressants
— R05DA09: Dextromethorphan
HCPCS
No data
Clinical
Clinical Trials
166 clinical trials
View more details

Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 29 | 1 | — | 1 | 4 | 35 | ||
Cough | D003371 | HP_0012735 | R05 | 2 | — | 3 | 1 | 1 | 7 |
Major depressive disorder | D003865 | EFO_0003761 | F22 | 2 | 3 | 1 | 1 | — | 6 |
Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | 2 | 1 | — | 6 |
Respiratory tract infections | D012141 | J06.9 | 1 | 1 | 3 | 2 | — | 6 | |
Pseudobulbar palsy | D020828 | EFO_1001131 | — | — | 1 | 3 | — | 4 | |
Postoperative pain | D010149 | G89.18 | — | — | — | 2 | 1 | 3 | |
Common cold | D003139 | EFO_0007214 | J00 | 1 | 1 | — | 1 | — | 3 |
Stroke | D020521 | EFO_0000712 | I63.9 | — | 1 | 1 | 1 | — | 3 |
Bronchitis | D001991 | J40 | — | — | — | 1 | 2 | 3 |
Show 11 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | C80 | 3 | — | 1 | — | 1 | 5 | |
Treatment-resistant depressive disorder | D061218 | 1 | 3 | 1 | — | — | 4 | ||
Rett syndrome | D015518 | F84.2 | — | 2 | 1 | — | 1 | 4 | |
Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 2 | 1 | — | — | 3 |
Schizophrenia | D012559 | EFO_0000692 | F20 | 2 | 2 | 1 | — | — | 3 |
Parkinson disease | D010300 | EFO_0002508 | G20 | — | 2 | 1 | — | — | 3 |
Pain | D010146 | EFO_0003843 | R52 | — | 1 | 1 | — | 1 | 3 |
Huntington disease | D006816 | G10 | 1 | — | 1 | — | — | 2 | |
Bipolar disorder | D001714 | EFO_0000289 | F30.9 | — | — | 2 | — | — | 2 |
Multiple sclerosis | D009103 | EFO_0003885 | G35 | — | 1 | 1 | — | — | 2 |
Show 13 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neuralgia | D009437 | EFO_0009430 | — | 5 | — | — | — | 5 | |
Hyperalgesia | D006930 | 1 | 2 | — | — | — | 3 | ||
Fibromyalgia | D005356 | EFO_0005687 | M79.1 | 1 | 1 | — | — | — | 2 |
Spinal cord injuries | D013119 | EFO_1001919 | — | 2 | — | — | — | 2 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 2 | — | — | — | 2 |
Smoking cessation | D016540 | EFO_0004319 | 1 | 1 | — | — | — | 1 | |
Migraine disorders | D008881 | EFO_0003821 | G43 | — | 1 | — | — | — | 1 |
Brain edema | D001929 | EFO_1000845 | G93.6 | — | 1 | — | — | — | 1 |
Dyskinesias | D020820 | G24 | — | 1 | — | — | — | 1 | |
Autistic disorder | D001321 | EFO_0003758 | F84.0 | — | 1 | — | — | — | 1 |
Show 14 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Drug interactions | D004347 | 2 | — | — | — | 1 | 3 | ||
Food-drug interactions | D018565 | 2 | — | — | — | — | 2 | ||
Prostatic neoplasms | D011471 | C61 | 2 | — | — | — | — | 2 | |
Infections | D007239 | EFO_0000544 | 1 | — | — | — | 1 | 2 | |
Melanoma | D008545 | 1 | — | — | — | — | 1 | ||
Mitochondrial diseases | D028361 | EFO_0000591 | 1 | — | — | — | — | 1 | |
Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 | ||
Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
Voice disorders | D014832 | 1 | — | — | — | — | 1 | ||
Mucociliary clearance | D009079 | 1 | — | — | — | — | 1 |
Show 1 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | — | — | — | — | 1 | 1 |
Attention deficit disorder with hyperactivity | D001289 | EFO_0003888 | F90 | — | — | — | — | 1 | 1 |
Breast neoplasms | D001943 | EFO_0003869 | C50 | — | — | — | — | 1 | 1 |
Pituitary dwarfism | D004393 | EFO_1001109 | E23.0 | — | — | — | — | 1 | 1 |
Sleep apnea syndromes | D012891 | EFO_0003877 | G47.3 | — | — | — | — | 1 | 1 |
Neurotoxicity syndromes | D020258 | G92 | — | — | — | — | 1 | 1 | |
Fatigue | D005221 | HP_0012378 | R53.83 | — | — | — | — | 1 | 1 |
Pneumonia | D011014 | EFO_0003106 | J18 | — | — | — | — | 1 | 1 |
Lung diseases | D008171 | EFO_0003818 | J98.4 | — | — | — | — | 1 | 1 |
Pulmonary fibrosis | D011658 | J84.10 | — | — | — | — | 1 | 1 |
Show 1 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | DEXTROMETHORPHAN |
INN | dextromethorphan |
Description | Dextromethorphan is a 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough. It has a role as a NMDA receptor antagonist, a neurotoxin, a xenobiotic, an environmental contaminant, an antitussive, a prodrug and a oneirogen. It is functionally related to a dextrorphan. It is an enantiomer of a levomethorphan. |
Classification | Small molecule |
Drug class | deuterated compounds; narcotic antagonists/agonists (morphinan derivatives) |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | COc1ccc2c(c1)[C@]13CCCC[C@@H]1[C@H](C2)N(C)CC3 |
Identifiers
PDB | — |
CAS-ID | 125-71-3 |
RxCUI | 3289 |
ChEMBL ID | CHEMBL52440 |
ChEBI ID | — |
PubChem CID | 5360696 |
DrugBank | DB00514 |
UNII ID | 7355X3ROTS (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
SIGMAR1
SIGMAR1
GRIN2C
GRIN2C
Organism
Homo sapiens
Gene name
SIGMAR1
Gene synonyms
OPRS1, SRBP
NCBI Gene ID
Protein name
sigma non-opioid intracellular receptor 1
Protein synonyms
Aging-associated gene 8 protein, hSigmaR1, SIG-1R, Sigma 1-type opioid receptor, Sigma1-receptor, Sigma1R, SR-BP, SR31747 binding protein 1, SR31747-binding protein
Uniprot ID
Mouse ortholog
Sigmar1 (18391)
sigma non-opioid intracellular receptor 1 (O55242)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:

Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 6,057 documents
View more details
Safety
Black-box Warning
Black-box warning for: Auvelity
Adverse Events
Top Adverse Reactions

Mock data
Subscribe for the real data
Subscribe for the real data
97,043 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more